(Q53521867)

15 May 2018

title

The standard of reporting of health-related quality of life in clinical cancer trials. (English)

1 reference

15 May 2018

1 reference

C W Lee

1

1 reference

15 May 2018

K N Chi

series ordinal

2

1 reference

15 May 2018

publication date

1 May 2000

1 reference

15 May 2018

Journal of Clinical Epidemiology

published in

1 reference

15 May 2018

volume

53

1 reference

15 May 2018

issue

5

1 reference

15 May 2018

page(s)

451-458

1 reference

15 May 2018

Reporting on quality of life in randomised controlled trials: bibliographic study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Quality of life assessment in pediatric oncology: a retrospective review of phase III reports

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Evaluating the impact of medical treatment on the quality of life: a 5-year update

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Assessment of quality of life in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Quality of life as outcome measures in randomized clinical trials. An overview of three general medical journals

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Guidelines for reporting results of quality of life assessments in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Factors of importance when evaluating quality of life in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

A perspective on the role of quality-of-life assessment in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Quality of life measures in health care. II: Design, analysis, and interpretation

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Quality-of-life assessment in cancer treatment protocols: research issues in protocol development

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Quality-of-life measurements in the evaluation of treatment: proposed guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Identifying relevant studies for systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

A Coefficient of Agreement for Nominal Scales

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Measuring quality of life in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Comparative evaluation of therapeutic approaches in stage III and IV squamous cell carcinoma of the thoracic esophagus with conventional radiotherapy and endoscopic treatment in combination and endoscopic treatment alone: a randomized prospective tr

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Pion radiation for high grade astrocytoma: results of a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Statistical problems in the reporting of clinical trials. A survey of three medical journals.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

A consumer's guide to subgroup analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Why are missing quality of life data a problem in clinical trials of cancer therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Missing quality of life data in cancer clinical trials: serious problems and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Do quality of life assessments make a difference in the evaluation of cancer treatments?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

A comparative analysis of quality of life data from a Southwest Oncology Group randomized trial of advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Growth curve model analysis for quality of life data.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Suggestions for the presentation of quality of life data from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Reporting on methods in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Randomisation and baseline comparisons in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

Adherence to published standards of reporting: a comparison of placebo-controlled trials published in English or German.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

A quality assessment of randomized control trials of primary treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2899%2900221-8

7 January 2021

10.1016/S0895-4356(99)00221-8

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

10812316

1 reference

15 May 2018